A 48-WEEK trial evaluating the
investigational integrase inhibitor
dolutegravir in treatment-naive
adults with HIV-1 infection, has
found that the proportion of study
participants who were virologically
suppressed (HIV-1 RNA 100,000 c/mL), the response rates
were 82% for DTG vs. 75% for RAL.
Prespecified secondary analyses
also supported non-inferiority of
dolutegravir to raltegravir; the
proportion of subjects without
treatment-related discontinuations
was 93% on dolutegravir and 92%
on raltegravir.
Median CD4 increases were also
similar in both groups (+230 cells/
mm3).
Virologic failure was also found to
occur in 5% of DTG subjects and 7%
of RAL subjects.The above article was sent to subscribers in Pharmacy Daily's issue from 30 Jul 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Jul 12
DEMENTIA Australia has appointed comedian Geraldine Hickey (pictured) as its newest Ambassador, coinciding with the Melbourne Memory Walk & Jog event taking place this Sun.
NEW research from the Monash Addiction Research Centre has highlighted a critical shortfall in the availability of Naloxone, a life-saving medication that reverses opioid overdoses, across community pharmacies in Australia’s most populous states.
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.